Our Pricing

Ozempic vs Wegovy for Weight Loss: Clinical Differences Explained

When researching ozempic vs wegovy weight loss uk options, many patients discover these medications contain the same active ingredient—semaglutide—yet differ significantly in licensed indications, dosing protocols, and regulatory approval for weight management. At Cured Pharmacy, our UK-registered clinical team helps patients understand which semaglutide treatment aligns with their health profile, offering transparent pricing and expert guidance throughout your weight management journey.

What Is the Difference Between Ozempic and Wegovy?

Both Ozempic and Wegovy contain semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics natural hormones regulating appetite and blood glucose [1]. The critical distinction lies in their MHRA-licensed indications and maximum therapeutic doses. Ozempic is licensed exclusively for type 2 diabetes management at doses up to 1mg weekly, whilst Wegovy is specifically licensed for chronic weight management at doses reaching 2.4mg weekly [2].

This dosing difference is clinically significant. The STEP 1 trial demonstrated that semaglutide 2.4mg (the Wegovy dose) produced an average 14.9% body weight reduction over 68 weeks in adults with obesity, compared to 2.4% with placebo [2]. Ozempic's lower maximum dose, whilst effective for glycaemic control, was not studied or approved at the higher concentrations shown to optimise weight loss outcomes.

In the UK, prescribing Ozempic off-label for weight loss—whilst technically possible—raises regulatory and supply concerns. The MHRA and NHS have repeatedly emphasised that Ozempic should be reserved for patients with type 2 diabetes, particularly given ongoing supply pressures affecting those with the licensed indication [3]. Wegovy, by contrast, is purpose-designed and licensed for weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities, subject to prescriber assessment.

How Semaglutide Works for Weight Management

Clinical trials consistently demonstrate that semaglutide's weight loss effects are dose-dependent. In the STEP programme, participants receiving the 2.4mg weekly dose experienced significantly greater weight reduction than those on lower doses, with the majority of weight loss occurring within the first 60 weeks of treatment [2]. Importantly, these trials required participants to combine medication with reduced-calorie diets and increased physical activity, underscoring that semaglutide is a therapeutic adjunct rather than a standalone solution.

Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), regularly advises patients that successful weight management with semaglutide requires commitment to lifestyle modifications alongside medication. The combination approach addresses both the biological and behavioural components of obesity, maximising long-term outcomes and sustainability after treatment concludes.

Mechanism of Action

Semaglutide activates GLP-1 receptors in the brain's appetite regulation centres, particularly the hypothalamus, reducing hunger signals and increasing satiety after meals [1]. This hormonal pathway also slows gastric emptying, prolonging the feeling of fullness and reducing overall caloric intake. Unlike stimulant-based appetite suppressants, semaglutide works through natural metabolic pathways, offering a physiological approach to weight reduction.

Wegovy Dosing Protocol and Titration Schedule

The recommended Wegovy titration follows this pathway: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, then 2.4mg as the maintenance dose [4]. If patients experience persistent gastrointestinal symptoms at any stage, UK prescribers may extend the duration at the current dose before advancing, prioritising tolerability and treatment adherence over rapid escalation.

At Cured Pharmacy, each Wegovy prescription includes detailed administration guidance and access to our UK clinical team throughout your titration journey. All patients complete a comprehensive medical assessment before treatment initiation, ensuring semaglutide is appropriate for your individual health profile and that potential contraindications are identified early.

Why Gradual Dose Escalation Matters

Wegovy follows a structured 16-week titration schedule, beginning at 0.25mg weekly and gradually increasing to the maintenance dose of 2.4mg weekly [4]. This gradual escalation minimises gastrointestinal side effects—the most commonly reported adverse events in clinical trials—by allowing the digestive system to adapt to semaglutide's effects on gastric motility. Patients who attempt to escalate doses too quickly often experience increased nausea, vomiting, and treatment discontinuation.

Ozempic vs Wegovy UK Pricing and Availability

Wegovy is available at Cured Pharmacy from £79.00, with transparent upfront pricing displayed before you begin your clinical consultation. This competitive rate includes your medication, UK prescriber assessment, and discreet delivery to your address. Unlike some providers who obscure costs until after lengthy consultations, we believe patients deserve pricing clarity from the outset.

Ozempic availability for weight management has become increasingly restricted across UK pharmacies due to supply prioritisation for patients with type 2 diabetes. The MHRA has issued guidance discouraging off-label prescribing of Ozempic for weight loss, recommending that patients seeking semaglutide for obesity management be directed toward Wegovy instead [3]. This regulatory position reflects both the medication's licensed indication and the need to protect supply for those with diabetes who depend on Ozempic for glycaemic control.

When comparing costs, it's essential to consider the complete treatment pathway rather than isolated pen prices. Wegovy's higher maximum dose means you're receiving the evidence-based concentration shown in clinical trials to optimise weight loss outcomes, rather than a lower dose originally calibrated for diabetes management. Our pricing structure at Cured Pharmacy ensures you receive genuine UK-licensed medication dispensed by our GPhC-registered pharmacy (9012511), with every prescription reviewed by qualified UK prescribers.

Side Effects and Safety Considerations

More serious but rare risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies but not conclusively demonstrated in humans) [4]. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Your UK prescriber will screen for these contraindications during your clinical assessment before approving any semaglutide prescription.

Patients with a history of diabetic retinopathy should discuss potential risks with their prescriber, as rapid glucose reduction in diabetes patients has been associated with temporary worsening of retinal conditions [1]. Additionally, semaglutide may increase heart rate slightly in some individuals, warranting caution in those with pre-existing cardiovascular conditions. Our clinical team at Cured Pharmacy conducts thorough medical history reviews to identify any factors that might increase your risk profile or require additional monitoring during treatment.

Common Adverse Events

The most frequently reported side effects of semaglutide across both Ozempic and Wegovy include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [2][4]. These gastrointestinal symptoms typically emerge during dose escalation and often diminish as treatment continues, though individual experiences vary considerably. In the STEP trials, approximately 7% of participants discontinued Wegovy due to gastrointestinal adverse events.

Who Is Eligible for Wegovy in the UK?

Private prescribing pathways, such as those offered through Cured Pharmacy, may apply slightly broader criteria whilst still adhering to safe prescribing principles and MHRA licensing. Our UK prescribers assess each patient individually, considering BMI, weight-related health conditions, previous weight loss attempts, and overall medical suitability. This personalised approach ensures that semaglutide is prescribed only when clinically appropriate and likely to benefit the patient.

Wegovy is not suitable for everyone. Contraindications include pregnancy or planned pregnancy (adequate contraception is essential during treatment), breastfeeding, age under 18 years, and certain pre-existing medical conditions as previously discussed [4]. Your online consultation will systematically assess these factors, with our clinical team available to answer questions throughout the process. All prescription medications at Cured Pharmacy require approval from a UK-registered prescriber following comprehensive medical assessment—this is a regulatory requirement and a patient safety priority.

NICE Guidance and Clinical Criteria

The National Institute for Health and Care Excellence (NICE) recommends semaglutide 2.4mg (Wegovy) for weight management in adults with an initial BMI of 35 kg/m² or above, or 30-34.9 kg/m² with at least one weight-related comorbidity such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease [5]. Treatment should be discontinued if patients do not achieve at least 5% weight loss after 12 weeks at the maintenance dose, as this indicates insufficient therapeutic response.

Scientific References

1. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Medicines and Healthcare products Regulatory Agency. (2023). Semaglutide (Ozempic) for type 2 diabetes: ensuring appropriate use amid supply shortages. Drug Safety Update, 16(8). https://www.gov.uk/drug-safety-update
4. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE guidance. https://www.nice.org.uk/guidance/ta875

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed for chronic weight management in adults with obesity or overweight with weight-related comorbidities, and must be used alongside a reduced-calorie diet and increased physical activity. Individual results may vary. Treatment is subject to prescriber approval following comprehensive medical assessment.